BTKi Therapy for CLL and MCL: SOHO 2023
New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023

Released: October 04, 2023

Catherine C. Coombs
Catherine C. Coombs, MD, MS
Toby A Eyre
Toby A Eyre, MBChB, MD

Activity

Progress
1
Course Completed

In this episode, Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, discuss key trials presented at SOHO 2023 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:

  • Matching-adjusted indirect comparison of 3 randomized phase III trials of ibrutinib for relapsed/refractory CLL
  • Meta-analysis of cardiovascular adverse events with second-generation BTK inhibitors in CLL
  • BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
  • ViPOR: venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide for relapsed/refractory and treatment-naive MCL